Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Hongyan Wang, PhD, Ramasamy Santhanam, Ph.D, Zhiliang Xie, MD, Xiaomeng Huang, Ming Chiu, Mitch A. Phelps, PhD, Alison R Walker, MD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, James Lee, PhD, Natarajan Muthusamy, DVM, Ph.D, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2013) 122 (21): 3933.

https://doi.org/10.1182/blood.V122.21.3933.3933

Published: 2013

Journal Articles

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Blood (2012) 120 (21): 2422.

https://doi.org/10.1182/blood.V120.21.2422.2422

Published: 2012

Journal Articles

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Hongyan Wang, Ping Chen, Ph.D., Jiang Wang, Ramasamy Santhanam, Ph.D, Josephine Aimiuwu, Vijayasaradhi UV, Zhongfa Liu, Sebastian Schwind, MD, Alice S. Mims, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Michael R. Grever, MD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Ramiro Garzon, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3578.

https://doi.org/10.1182/blood.V120.21.3578.3578

Published: 2012

Journal Articles

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Rebecca B Klisovic, MD, Hongyan Wang, Alison Walker, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Jiang Wang, Celia Garr, RN, Adam Norris, John C. Byrd, MD, Michael R. Grever, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3616.

https://doi.org/10.1182/blood.V120.21.3616.3616

Published: 2012

Journal Articles

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Xiaomeng Huang, Sebastian Schwind, MD, Bo Yu, Ph.D, Jiuxia Pang, Ramasamy Santhanam, Ph.D, Kenneth K. Chan, Ph.D, Ramiro Garzon, MD, William Blum, MD, Clara D. Bloomfield, MD, Shujun Liu, Ph.D, Danilo Perrotti, MD, Ph.D, Robert J. Lee, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, L. James Lee, Ph.D, Guido Marcucci, MD

Blood (2011) 118 (21): 81.

https://doi.org/10.1182/blood.V118.21.81.81

Published: 2011

Journal Articles

Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes

Reda Z Mahfouz, MD, Ania Jankowska, PhD, Quteba Ebrahem, MD, Zhenbo Hu, MD, Kenneth K. Chan, Ph.D, Donald Lavelle, Ph.D., Joseph DeSimone, PhD, Mikkael A. Sekeres, MD, MS, Ramon V. Tiu, MD, BS, Jaroslaw P. Maciejewski, MD, PhD, Yogen Saunthararajah, M.D.

Blood (2011) 118 (21): 1434.

https://doi.org/10.1182/blood.V118.21.1434.1434

Published: 2011

Journal Articles

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Ping Chen, Ph.D., William Blum, M.D., Josephine Aimiuwu, B.S., Vijayasarathi Upadhyayula, Ph.D., Zhongfa Liu, Ph.D., Shujun Liu, Ph.D., Jiuxia Pang, B.S., Alison Walker, M.D., Rebecca B. Klisovic, M.D., Ramiro Garzon, M.D., Michael R. Grever, M.D., Miguel Villalona-Calero, M.D., John C. Byrd, M.D., Kenneth K Chan, Ph.D., Guido Marcucci, M.D.

Blood (2009) 114 (22): 3782.

https://doi.org/10.1182/blood.V114.22.3782.3782

Published: 2009

NARROW

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Email alerts

ASH Publications

American Society of Hematology

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only